Joshua T. Brumm, CEO & President at Dyne Therapeutics, Inc. (DYN), sold 859,025 shares at $25.30 ($22.2M) on 2024-03-08, disclosed to the SEC on 2024-03-12.
Scheduled sale ($22.2M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.30 | 202,238 | $5.1M | 23.0% |
| 2 | $25.30 | 202,238 | $5.1M | 23.0% |
| 3 | $26.72 | 160,670 | $4.3M | 19.3% |
| 4 | $26.72 | 160,670 | $4.3M | 19.3% |
| 5 | $27.38 | 435 | $12K | 0.1% |
| 6 | $25.42 | 40,072 |
| $1.0M |
| 4.6% |
| 7 | $25.42 | 40,072 | $1.0M | 4.6% |
| 8 | $25.93 | 8,618 | $223K | 1.0% |
| 9 | $25.93 | 8,618 | $223K | 1.0% |
| 10 | $26.10 | 9,928 | $259K | 1.2% |
| 11 | $26.10 | 9,928 | $259K | 1.2% |
| 12 | $26.12 | 7,769 | $203K | 0.9% |
| 13 | $26.12 | 7,769 | $203K | 0.9% |
| Total | $25.89 avg | 859,025 | $22.2M | 100% |
| Filing → |
| DYN | SELL | 2024-03-11 | $470K | — | Filing → |
| DYN | SELL | 2024-03-01 | $5.1M | — | Filing → |
| DYN | SELL | 2024-01-04 | $9.7M | — | Filing → |